A single‑center retrospective study suggests a potential benefit of BTK inhibitor‑based therapy in patients with histologic transformation of Waldenström macroglobulinemia
Polatuzumab vedotin is an anti‑CD79b antibody‑drug conjugate that delivers the cytotoxic agent monomethyl auristatin E selectively to lymphoma cells.
The standard first‑line R‑CHOP regimen achieves cure in only approximately 50% of patients. Polatuzumab vedotin (Pola) is a novel antibody–drug conjugate targeting the B‑cell receptor component CD79b; however, evidence regarding its real‑world efficacy remains relatively limited. This retrospective study aims to evaluate the clinical efficacy of Pola in combination therapy.
Polatuzumab vedotin is a promising first‑line treatment for diffuse large B‑cell lymphoma.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report
- Loncastuximab in high‑risk and heavily pre‑treated relapsed/refractory diffuse large B‑cell lymphoma: a real‑world analysis from 21 US centers